Sugi Predict

Sugi Predict / Compounds / Rosterolone

Rosterolone

Rosterolone

SCHEMBL141283

CCC[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)C[C@H](C)[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHBG P04278 6/20 0.57
▸ MAPK1 P28482 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ AR P10275 2/20 0.38
▸ HSD17B3 P37058 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NR3C1 P04150 2/20 0.36
▸ PGR P06401 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ ABCB11 O95342 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ AGTR1 P30556 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rosterolone SCHEMBL8724124 1.00 SHBG (0.57) SHBGMAPK1POLBARHSD17B3
Rosterolone SCHEMBL7094611 1.00 SHBG (0.57) SHBGMAPK1POLBARHSD17B3
SCHEMBL9706258 0.93 SHBG (0.57) SHBGMAPK1POLBARHSD17B3
SCHEMBL9706264 0.93 SHBG (0.57) SHBGMAPK1POLBARHSD17B3
SCHEMBL10408625 0.92 SHBG (0.56) SHBGMAPK1POLBARHSD17B3
SCHEMBL10408627 0.92 SHBG (0.56) SHBGMAPK1POLBARHSD17B3
SCHEMBL10408955 0.91 SHBG (0.55) SHBGMAPK1POLBARHSD17B3
SCHEMBL10408953 0.91 SHBG (0.55) SHBGMAPK1POLBARHSD17B3
SCHEMBL10883090 0.91 SHBG (0.57) SHBGMAPK1POLBARMEN1
SCHEMBL10883085 0.91 SHBG (0.57) SHBGMAPK1POLBARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180177759-A1 COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA-GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) 2018-06-28 — — US claimed
EP-3285753-A1 COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA -GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) 2018-02-28 — — EP claimed
WO-2016170102-A1 COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA -GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) 2016-10-27 — — WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-4892867-A Antiandrogenic 17-alpha-alkyl steroids SCHERING AKTIENGESELLSCHAFT (DE) 1990-01-09 — — US claimed
EP-0027961-B1 17-ALPHA-SUBSTITUTED STEROIDS, PREPARATIONS CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION SCHERING AKTIENGESELLSCHAFT (DE) 1983-01-12 — — EP claimed
EP-0027961-A1 17-alpha-substituted steroids, preparations containing them and process for their production SCHERING AKTIENGESELLSCHAFT (DE) 1981-05-06 — — EP claimed
US-20260124244-A1 MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES STELLULAR BIO, INC. (US) 2026-05-07 — — US disclosed
EP-4646217-A1 MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES Stellular Bio, Inc. (US) 2025-11-12 — — EP disclosed
WO-2024148315-A1 MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES STELLULAR BIO, INC. (US) 2024-07-11 — — WO disclosed
US-20230174939-A1 NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS STELLULAR BIO, INC. (US) 2023-06-08 — — US disclosed
US-4558041-A ACNE, DEPILATORIES; BALDNESS SCHERING AKTIENGESELLSCHAFT (DE) 1985-12-10 — — US disclosed
US-4456600-A Antiandrogenic 17α-alkyl steroids SCHERING, AKTIENGESELLSCHAFT (A.G.) (DE) 1984-06-26 — — US disclosed
EP-0027961-B1 17-ALPHA-SUBSTITUTED STEROIDS, PREPARATIONS CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION SCHERING AKTIENGESELLSCHAFT (DE) 1983-01-12 — — EP disclosed
US-4344941-A Antiandrogenic 17α-substituted steroids SCHERING AKTIENGESELLSCHAFT (A.G.) (DE) 1982-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124244-A1 MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES MYH10, PDGFA, MPL SHBG 1681/4885MAPK1 603/4885POLB 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.